Second child free of cancer after treatment with Cellectis' UCART 19

9 May 2016
2019_biotech_test_vial_discovery_big

A second baby with acute lymphoblastic leukemia (ALL) who received the experimental UCART19 injection of French biotech company Cellectis (Euronext Paris: ALCLS) remains in remission six months after treatment, according to reports.

The 16-month-old girl was found to be recovering from the previously incurable disease at Great Ormond Street Hospital in London, providing further excitement about the potential of Cellectis’ allogeneic gene-edited chimeric antigen receptor T-cell (CAR-T) immunotherapy in fighting cancer.

News on the latest case comes as the first infant continues to be in remission almost a year after receiving the treatment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology